MYNZ_OUT_1 [2025-04-29 11:13:22 -0400] 5743 Bytes | 1573 tokens | Cum: 1573 tkns (19.66% of 8k)
==========================================================================

Good morrow, traveler. 'Tis 11:13 AM on Tue Apr 29, 2025, and lo, Mainz Biomed N.V. (MYNZ) hath gained ground from $3.70 unto $4.22. Shall we seize upon this chance, or tarry and watch?

--- COMPANY PROFILE ---
Company: Mainz Biomed N.V. (MYNZ)
IPO: 2021-11-05 (3 Years Ago)
Market Cap: $6,509,279
Shares Outstanding: 2,220,000
Exchange: XNAS
Description: Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Here’s a list of headlines for Mainz Biomed N.V.:

Today 08:01AM - Mainz Biomed Enters into Technology Partnership with EDX Medical Group
Apr-28-25 08:01AM - Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Apr-01-25 08:01AM - Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Mar-28-25 06:49AM - Mainz enrols first subject in study to evaluate colorectal cancer test
Mar-27-25 09:01AM - Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Mar-20-25 10:35AM - Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
Mar-19-25 05:35PM - Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates
Mar-13-25 08:01AM - Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
Mar-03-25 08:01AM - Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
Feb-20-25 08:01AM - Mainz Biomed Expands into Switzerland with labor team w
Feb-11-25 08:01AM - Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Jan-27-25 08:01AM - Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Jan-21-25 08:01AM - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
Dec-20-24 10:31AM - Mainz Biomed partners with Quest for colorectal cancer screening test
Dec-19-24 08:01AM - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Dec-16-24 05:00PM - Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
Dec-12-24 08:00PM - Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
Nov-29-24 08:45AM - Mainz Biomed Announces Stock Split
Nov-13-24 07:23PM - The Oncology Bet Is Already Paying Off For Pfizer
Nov-12-24 09:00AM - Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
Oct-22-24 08:10AM - Mainz Biomed restructured operations, implemented cost reductions
Oct-21-24 08:01AM - Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Prior AI Reports for MYNZ:
1. 2025-04-02 – Score: 25 – Target: 3.8775 – Highs: 3.6400 / 3.5890 / 3.13
lack-of-investor-interest-plagues-company-amidst-downward-trend
2. 2025-03-20 – Score: 1 – Target: 5.1450 – Highs: 5.3400 / 4.8250 / 4.80
mainz-biomed-showing-signs-of-recovery-despite-bearish-trend

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-01T12:01:00Z - Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
B2 - 2025-03-03T13:01:00Z - Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
B3 - 2025-02-20T13:01:00Z - Mainz Biomed Expands into Switzerland with labor team w
B4 - 2025-01-21T13:01:00Z - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
B5 - 2024-12-19T13:01:00Z - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
B6 - 2024-12-13T01:00:00Z - Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Mainz Biomed N.V. (MYNZ).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

MYNZ_OUT_3 [2025-04-29 11:13:23 -0400] 804 Bytes | 215 tokens | Cum: 1790 tkns (22.38% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/01/3053314/0/en/Mainz-Biomed-Reports-2024-Financial-Results-and-Provides-Corporate-Update.htmlMainz Biomed reported a 33% increase in lab network revenue, a 30% decrease in operating loss, and an 18% decrease in net loss in 2024. The company made progress with strategic partnerships and its next-generation colorectal cancer screening product.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MYNZ_OUT_5 [2025-04-29 11:13:24 -0400] 897 Bytes | 267 tokens | Cum: 2059 tkns (25.74% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-29T12:01:03Z - Mainz BioMed N.V. / NL0015000LC2...
A2 - 2025-04-29T12:31:41Z - Mainz Biomed Enters into Technology Partnership with EDX Medical Group | Taiwan News | Apr. 29, 2025...
A3 - 2025-04-29T12:24:12Z - Mainz Biomed Enters into Technology Partnership with EDX Medical Grou By Investing.com...
A4 - 2025-04-29T12:18:07Z - Mainz Biomed Enters into Technology Partnership with EDX Medical Group...
A5 - 2025-04-29T12:10:33Z - Mainz Biomed Enters into Technology Partnership with EDX Medical Group...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MYNZ_OUT_7 [2025-04-29 11:13:25 -0400] 1181 Bytes | 317 tokens | Cum: 2378 tkns (29.73% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Mainz BioMed N.V. / NL0015000LC2**Date: 2025-04-29Source: {'uri': 'ad-hoc-news.de', 'dataType': 'news', 'title': 'Ad Hoc News'}URL: https://www.ad-hoc-news.de/boerse/corporate-news/mainz-biomed-n-v-nl0015000lc2/67171718BERKELEY, US and MAINZ, Germany - April 29, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MYNZ_OUT_9 [2025-04-29 11:13:25 -0400] 1181 Bytes | 252 tokens | Cum: 2632 tkns (32.90% of 8k)
==========================================================================

Showing A1 (chunk 2 of 7): o improve access to high-quality cancer diagnostics in the UK," said Guido Baechler, Chief Executive Officer of Mainz Biomed. "By merging our expertise in molecular diagnostics with EDX Medical's excellent capabilities, we can provide a highly reliable and meaningful contribution to early cancer detection and prevention." Dr Mike Hudson, CEO of EDX Medical, said: " We are dedicated to making the very best diagnostic tests available to patients and healthcare professionals and are continuously looking to improve the performance of cancer testing by incorporating molecular biomarkers that can transform early cancer detection. We are delighted to form this technology partnership which will help us achieve this aim." Please visit Mainz Biomed's official website for investors at mainzbiomed.com/investors/ for more information Please follow us to stay up to date:

LinkedIn

X (Previously Twitt

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MYNZ_OUT_11 [2025-04-29 11:13:26 -0400] 1183 Bytes | 267 tokens | Cum: 2901 tkns (36.26% of 8k)
==========================================================================

Showing A1 (chunk 3 of 7): er)

Facebook About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook. About EDX Medical Group EDX Medical Group plc is headquartered in Cambridge, UK, and is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). EDX

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MYNZ_OUT_13 [2025-04-29 11:13:27 -0400] 1181 Bytes | 262 tokens | Cum: 3165 tkns (39.56% of 8k)
==========================================================================

Showing A1 (chunk 4 of 7): Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson. By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally. For more information, please visit www.edxmedical.com. For media inquiries as to Mainz Biomed: MC Services AG

Maximilian Schur / Simone Neeten

+49 211 529252 20

[email protected] For investor inquiries, please contact [email protected] For media inquiries as to

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MYNZ_OUT_15 [2025-04-29 11:13:28 -0400] 1181 Bytes | 277 tokens | Cum: 3444 tkns (43.05% of 8k)
==========================================================================

Showing A1 (chunk 5 of 7): EDX Medical Group: Media House International

Ramsay Smith

+44 (0)7788 414856

[email protected]

Gary McQueen

+44 (0)7834 694609

[email protected] Forward-Looking Statements Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MYNZ_OUT_17 [2025-04-29 11:13:29 -0400] 1181 Bytes | 250 tokens | Cum: 3696 tkns (46.20% of 8k)
==========================================================================

Showing A1 (chunk 6 of 7): risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed o

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MYNZ_OUT_19 [2025-04-29 11:13:30 -0400] 815 Bytes | 195 tokens | Cum: 3893 tkns (48.66% of 8k)
==========================================================================

Showing A1 (chunk 7 of 7): n April 9, 2024. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MYNZ_OUT_21 [2025-04-29 11:13:30 -0400] 238 Bytes | 59 tokens | Cum: 3954 tkns (49.43% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MYNZ_OUT_23 [2025-04-29 11:13:32 -0400] 251 Bytes | 78 tokens | Cum: 4035 tkns (50.44% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

MYNZ_OUT_25 [2025-04-29 11:13:38 -0400] 4946 Bytes | 1196 tokens | Cum: 5234 tkns (65.42% of 8k)
==========================================================================

This is our set of metrics for Mainz Biomed N.V..
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 402,934 | Perf Month: 13.69% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 256.86K | Perf Quarter: -21.43% | Short Float: 2.40% | ROE: - |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 5.93 | Index: - | Short Ratio: 0.27 | ROI: - |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 57.88 | Market Cap: 12.36M | Short Interest: 0.07M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.47 | Shs Outstand: 3.04M | Beta: 0.48 | EPS Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: 23.63% | Shs Float: 2.89M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -4.28% | Inst Own: 8.07% | Sales past 5Y: 19.40% | Earnings: Apr 01 BMO |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -52.15% | Insider Own: 4.98% | Employees: 26 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: 27.59% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading by Mainz Biomed N.V. officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.2232
Average Volume: 230163.19
30-Day High: 4.2232
30-Day Low: 2.93
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Mainz Biomed N.V. (MYNZ).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Mainz Biomed N.V..

2) MARKET_SCORE[]
This conversation was initiated because MYNZ is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for MYNZ.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, MYNZ could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect MYNZ to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Mainz Biomed N.V..

11) ETHICAL_RATING[]
Rate Mainz Biomed N.V.’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Mainz Biomed N.V..
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

MYNZ_IN_27 [2025-04-29 11:13:39 -0400] 126 Bytes | 29 tokens | Cum: 5474 tkns (68.42% of 8k)
==========================================================================

====================================
[2025-04-29 11:13:39] # Analysis Completed
Elapsed Time: 17.49 seconds